EY’s Arda Ural: Big pharma is driving a rebound in biopharma and medtech M&A

The most sought-after targets are small- to mid-sized companies focused on high-growth therapeutic areas, such as oncology, cardiometabolic, immunology, central nervous system and rare diseases.